drugset / Trial / NCT05656521
101-PGC-005 for the Treatment of COVID-19
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a prospective, randomized, comparative, multi-centric, adaptive design clinical study to evaluate efficacy, safety, and tolerability of 101-PGC-005 ('005) when used alongside standard of care (SOC) for the treatment of hospitalized patients with coronavirus disease (COVID-19).
Timeline
- Start
- 2023-01-31
- Primary completion
- 2023-04-21
- Completion
- 2023-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 101-PGC-005 | Unknown | 20 mg | Intravenous |
| Comparator | Dexamethasone | Small molecule | 6 mg | Other |